S

Seagen Inc
F:SGT

Watchlist Manager
Seagen Inc
F:SGT
Watchlist
Price: 208.6 EUR Market Closed
Market Cap: 39.4B EUR
Have any thoughts about
Seagen Inc?
Write Note

Gross Margin
Seagen Inc

75.4%
Current
82%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.4%
=
Gross Profit
1.7B
/
Revenue
2.3B

Gross Margin Across Competitors

Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 314.7B USD
Gross Margin
67%
Country US
Market Cap 157B USD
Gross Margin
60%
Country US
Market Cap 115.9B USD
Gross Margin
86%
Country US
Market Cap 112.2B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 82.6B USD
Gross Margin
87%
Country NL
Market Cap 34.5B EUR
Gross Margin
89%
Country US
Market Cap 31.5B USD
Gross Margin
85%
No Stocks Found

Seagen Inc
Glance View

Market Cap
39.3B EUR
Industry
Biotechnology

Seagen Inc. is a leading biotechnology company focused on developing innovative therapies for cancer treatment using its pioneering antibody-drug conjugate (ADC) technology. Founded in 1998, Seagen's mission is rooted in the belief that targeted therapies can improve the lives of cancer patients. The company has gained attention in the oncology space with its flagship products, such as Adcetris (brentuximab vedotin) and Padcev (enfortumab vedotin), which target specific cancer cells while minimizing damage to healthy tissue. This approach not only enhances efficacy but also helps in reducing side effects commonly associated with traditional chemotherapy. With a strong pipeline of investigational therapies that leverage their ADC platform, Seagen is positioned to be a transformative player in the oncology market. For investors, Seagen represents a compelling opportunity within the biotech sector, especially as demand for effective cancer treatments continues to grow. The company is actively expanding its product portfolio through strategic partnerships and collaborations, bolstering its capabilities in research and development. Financially, Seagen has demonstrated solid sales growth driven by its approved products, and it is continually working towards regulatory approvals for its pipeline candidates. As the landscape of cancer treatment evolves and personalized medicine becomes increasingly important, Seagen's innovative approach and commitment to delivering better patient outcomes make it a company to watch for those interested in the future of oncology and of the broader biotechnology market.

SGT Intrinsic Value
146.49 EUR
Overvaluation 30%
Intrinsic Value
Price
S

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.4%
=
Gross Profit
1.7B
/
Revenue
2.3B
What is the Gross Margin of Seagen Inc?

Based on Seagen Inc's most recent financial statements, the company has Gross Margin of 75.4%.